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ABSTRACT 
RELATIONSHIP BETWEEN HPV VACCINATION AND SEXUAL ACTITIVY, 
HEALTH CARE UTILIZATION, AND PERCIEVED RISK 
 
by 
 
Danielle L. Jirovec 
 
The University of Wisconsin – Milwaukee, 2013 
Under the Supervision of Professor Diane M. Reddy 
 
 
The relationship between sexual activity, sexual health care utilization, and perceived risk 
for HPV-related outcomes was examined in sample of college women, to explore recent 
concerns that HPV vaccination may be related to an increase in risky sexual behaviors. 
Vaccinated and not vaccinated women completed an anonymous, online survey including 
age of vaccination, age at each sexual partner, condom use, use and intentions to use 
sexual health care services, and perceptions of risk. Vaccinated women also reported 
perceptions of change because of vaccination. Women were matched on age, race, and 
poverty status. Number of partners since vaccination was calculated among the 
vaccinated women as partners at or after age of vaccination. Number of partners since 
vaccination for not vaccinated women was calculated using the age of vaccination of the 
matched pair, to allow comparison across equivalent time intervals. Number of vaginal, 
oral received, and anal partners were not different for vaccinated and not vaccinated 
women. Although, after vaccination, women who received the vaccine reported 
performing oral sex on a larger number of partners than not vaccinated women, the 
number of vaginal, oral, and anal sex partners for which a condom was not used was not 
different for vaccinated and not vaccinated women. Therefore, the number of partners 
from which STI infection was likely was similar for all women. Although use of sexual 
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health care services since vaccination was not different for vaccinated and not vaccinated 
women, not vaccinated women reported higher intentions to receive a pelvic exam in the 
next year and a Pap smear in the next three years than vaccinated women. Intentions to 
receive an STI test in the next year were not different, however. Perceptions of risk for 
HPV-related outcomes were also not different for vaccinated and not vaccinated women. 
Among vaccinated women, the majority reported they had not changed their sexual 
activity, condom use, or use of health care services because of the vaccine. This study 
indicates that HPV vaccination is not related to greater risky sexual activity but that 
efforts to increase intentions to use sexual health care services among vaccinated women 
should be addressed.  
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Genital human papillomavirus (HPV) is a sexually transmitted infection (STI) 
capable of infecting males and females through sexual activity including vaginal, penile, 
anal, or oral contact (US Department of Health and Human Services [HHS], 2012b). 
HPV is the most common STI in the United States (US) (Centers for Disease Control and 
Prevention [CDC], 2012), currently infecting approximately 79 million Americans, and 
the CDC estimates another 14 million people will become infected with HPV each year 
(CDC, 2013). Over 80% of sexually active women may contract HPV by the time they 
are 50 years old (CDC, 2007). Individuals are often unaware they have an HPV infection 
since the virus often presents no symptoms. The infection may persist for a few years and 
eventually go away without treatment (HHS, 2012b). In other cases, the HPV virus may 
persist for longer periods of time and may present symptoms such as genital warts or 
cervical cell changes. 
There are over 40 types of genital HPV classified as low-risk and high-risk types. 
Two low-risk types, 6 and 11, cause 90% of cases of genital warts in males and females 
(HHS, 2012b). The high-risk types of HPV can cause cancer of the vulva, vagina, penis, 
anus, cervix, and head and neck. Two of these high-risk types, 16 and 18, cause 70% of 
cervical cancer cases and almost 50% of vaginal, vulvar, and penile cancers. HPV 16 also 
causes about 85% of anal cancer cases (HHS, 2012b). 
 The risk of cervical cancer from HPV infection is of great importance to health 
officials and has been in the forefront of HPV concerns since cervical cancer rates are 
much higher than the other cancer rates caused by HPV. In 2007, the year of the most 
recent estimates, 12,280 women in the US were diagnosed with cervical cancer and 4,021 
women in the US died from cervical cancer (CDC, 2010b). HPV is found in 99% of 
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cervical cancer cases, with HPV types 16 and 18 being the cause of 70% of cervical 
cancer cases (National Cervical Cancer Coalition [NCCC], 2012). The treatment of 
genital warts and cervical cancer in the US each year is estimated to be $4 billion. The 
cost of treatment for the other cancers caused by HPV increases this economic burden 
even further (CDC, 2007). 
 In June 2006, the Food and Drug Administration (FDA) approved the Gardasil 
vaccine, a series of three doses given over a period of six months, for girls aged nine 
through 26 to protect against HPV types 6, 11, 16 and 18 (CDC, 2007). In 2007, the 
Advisory Committee on Immunization Practices (ACIP) began recommending, and 
continues to recommend, females age 11 through 12 receive the vaccine and females 13 
through 26 receive a ‘catch-up’ vaccine if they did not receive it at a younger age (CDC, 
2007). 
 In October 2009, the FDA approved a second brand of the HPV vaccine for 
females 10 through 25 years, Cervarix. This vaccine protects against HPV types 16 and 
18, but not against HPV types 6 and 11 (CDC, 2010a); thus it does not provide protection 
from HPV-related genital warts. Like Gardasil, Cervarix is a series of three doses 
administered over a six-month period. In 2010, ACIP modified its recommendation for 
females 11 through 26 to include Cervarix (CDC, 2010a), so providers and patients can 
choose either vaccine brand. 
 The benefits of the HPV vaccines are documented: vaccinating individuals against 
HPV will slow its spread, reduce the prevalence of the disease, and thereby reduce the 
prevalence of genital warts and cancers caused by HPV. Clinical trials with women 
indicate that the HPV vaccine is 100% effective in preventing changes in cervical cells 
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and anal infection caused by HPV 16 or 18; it is also 98.9% effective in preventing 
external genital warts (NCCC, 2012). The vaccines do not treat HPV, however. For 
individuals already exposed to a strain of HPV, the vaccine cannot provide treatment. 
The vaccine will, however, still be effective against HPV strains the individual has not 
yet been exposed to (CDC, 2007). Therefore, the vaccine is most effective when the 
series of three doses are completed prior to initiation of sexual activity, when HPV 
infection is most likely to occur. 
 Despite literature on the benefits of the HPV vaccine and the CDC’s 
recommendation for women to receive it, vaccination rates remain low in the US. The 
2010 National Immunization Survey of the CDC shows that only 48.7% of girls age 13 
through 17 in the US (and 54.4% in Wisconsin) have received at least one dose of the 
HPV vaccine and, among those, only 69.6% in the US (and 44.1% in Wisconsin) have 
received the complete set of three doses (CDC, 2011). These vaccination rates, both for 
the nation and Wisconsin, are well below Healthy People 2020’s targeted goal for 80% of 
females 13 through 15 to receive all three doses of the HPV vaccine (HHS, 2012a). 
Research suggests several potential psychological and logistical barriers to HPV vaccine 
uptake. 
Among these barriers, concerns about the relationship between HPV vaccination 
and sexual activity have been widely publicized in mass media as a reason against HPV 
vaccination (Bristol, 2007), and may be a contributor to low vaccination rates (Davis, 
Dickman, Ferris, & Dias, 2004; Zimet et al., 2005). Both newspapers and magazines have 
featured articles discussing a potential link between HPV vaccination and increased 
sexual activity (Gibbs, 2006; O’Rourke, 2007). This possible relationship has also been 
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in the forefront of the debate over mandatory HPV vaccination. When current Texas 
governor, Rick Perry, proposed mandatory HPV vaccination for young girls, a major 
component of the debate against it was the concern that HPV vaccination may encourage 
sexual promiscuity (Root, 2011). Similar fears have been noted in other states (Charo, 
2007) and editorials have argued that the vaccine may give young girls permission to 
engage in sexual activity, that it will give them a false sense of security, and that it will 
lead them to be disinhibited toward sexual activity (Haber, Malow, & Zimet, 2007; 
Vamos, McDermott, & Daley, 2008). Likewise, a report in the Congressional Quarterly 
Researcher described the issue of HPV vaccination and its potential to encourage sexual 
activity, send an inconsistent message about sex, and be used as an excuse for 
promiscuity (Colin, 2007).  
 Beyond mass media, research has discussed the concerns about HPV vaccination 
and sexual activity for pediatricians, mothers, and young adult women. Although the 
relationship between HPV vaccination and sexual activity was not the initial focus of 
these studies, they nonetheless represent important background and support the need for 
further examination of the issue. Pediatricians perceived that potential barriers to HPV 
vaccination included parental concern that vaccination would lead to risky sexual activity 
(Kahn et al., 2005; Kahn et al., 2009) and that getting children vaccinated would “imply 
they condone premarital sex” (Kahn et al, 2009, p. 2327). Mothers reported concerns the 
vaccine would lead to an increase in risky sexual behaviors, promiscuity, and risk of 
other STIs because their daughters would believe they are protected against all STIs 
(Waller, Marlow, & Wardle, 2006; Perkins, Pierre-Joseph, Marquez, Iloka, & Clark, 
2010). Similarly, female focus group participants 16-26 years were concerned the HPV 
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vaccine would lead women to discard condom use and give up cervical cancer screening 
due to a false sense of security from the vaccine (Mortensen, 2010). Mass media and 
research both suggest the concern about HPV vaccination and sexual activity is an 
important issue requiring investigation. However, past research has not clearly defined 
“risky sexual activity.” It is necessary to clarify this term to further examine the possible 
relationship between HPV vaccination and sexual activity. 
Several factors may contribute to risky sexual activity and should be examined in 
relation to HPV vaccination. Younger age of first sexual intercourse (Kaestle, Halpern, 
Miller, & Ford, 2005) and a higher number of sexual partners (Peterman et al., 2000) are 
associated with testing positive for an STI. Because the HPV vaccine provides no 
protection against other STIs, condom use and STI screenings remain important. 
Although the HPV vaccine does provide protection against HPV types responsible for 
70% of cervical cancer cases, females can still become infected with HPV types not 
covered by the vaccine which are also capable of causing cervical cancer. Similarly, 
because the vaccine does not protect against the types of HPV already acquired, it 
remains important for females to continue with recommended cervical cancer screenings 
(CDC, 2007) if sexual initiation occurred before all three doses were received. Current 
recommendations are that women 21-29 years old receive a Pap smear every 3 years and 
women 30-65 receive a Pap smear every 5 years (American Cancer Society, 2012). 
Perceptions regarding risk of HPV, other STIs, and cervical cancer are also important 
factors to examine because of concern that decreased risk perceptions will lead to risky 
sexual behavior (Brabin et al., 2009). 
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 Each of these sexual health issues supports the need for research on their 
potential relationship to HPV vaccination. If research suggests there is a link between 
HPV vaccination and increased sexual risk taking, or decreased sexual health care 
utilization, it may prompt a necessary increase in communication to women and health 
care providers about the importance of safe sex practices and sexual health care 
utilization. If no such relationship emerges, the data can be utilized to combat concerns 
and therefore attempt to increase HPV vaccination rates (Schuler, Reiter, Smith, & 
Brewer, 2011). Therefore, research is necessary to examine the relationship between 
HPV vaccination and sexual activity, sexual health care utilization, and perceptions of 
risk regarding HPV and other STIs.  
 Few studies have examined the relationship between HPV vaccination and sexual 
activity. Taylor, Hariri, Sternberg, Dunne, and Markowitz (2011) collected data regarding 
number of lifetime sex partners and number of sex partners in the past year. The authors 
defined sex broadly: as vaginal, anal, or oral. Results showed 14-26 year old women who 
had ever had sex were more likely to be vaccinated for HPV than those who had never 
had sex. Women who reported a higher number of sexual partners ever were also more 
likely to have received the HPV vaccine. For a subset of women, 11-18 year olds, those 
who reported higher numbers of sexual partners ever also reported higher rates of 
vaccination. Although these results appear to suggest there is a relationship between HPV 
vaccination and sexual activity, the scope of the study was only to identify associations 
between HPV vaccination and sexual behavior, no information was collected regarding 
the timing of receipt of vaccines in respect to sexual activity. Therefore, no conclusions 
can be drawn about whether sexual activity increased more for vaccinated women than 
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not vaccinated women. Instead, the results could be explained by the fact that women 
who are more sexually active prior to vaccination were more likely to receive the 
vaccine.  
 Liddon, Leichliter, and Markowitz (2012) also examined the relationship between 
HPV vaccination and sexual activity, but reported different results than Taylor et al. 
(2011). Data was collected regarding age of first vaginal intercourse, number of lifetime 
partners, condom use consistency in the past four weeks, and receipt of a Pap smear and 
STI service in the past year. Their study revealed that, among 15-19 year olds, those who 
reported always or sometimes using condoms were more likely to be vaccinated than 
those who reported never using a condom. HPV vaccination was unrelated to having had 
vaginal intercourse, age at first intercourse (for 15-19 year olds only), number of sexual 
partners ever, consistency of condom use in the past four weeks (20-24 year olds only), 
receiving STI services in the past year, and having a Pap smear in the last year (for 20-24 
years olds only). For 20-24 year olds, age at first vaginal intercourse and receipt of a Pap 
smear in the past year were unrelated to HPV vaccination when other variables were 
controlled for. As with Taylor et al. (2011), the purpose of this study was to examine 
associations between HPV vaccination and sexual behavior, so no data was collected 
about the age of HPV vaccination. Therefore, no conclusions can be made about sexual 
activity before and after vaccination. Instead, results suggest that, for a subset of women, 
those who receive the HPV vaccine may actually report safer sexual practices: more 
women who report always or consistently using a condom are vaccinated than those who 
report never using a condom.  
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 These studies were conducted in 2006-2008 (Liddon et al., 2012) and 2007-2008 
(Taylor et al., 2011), shortly after the first HPV vaccine was approved by the FDA in 
2006 and recommended by ACIP in 2007. Current research is needed to explore the 
relationship between HPV vaccination and sexual practices since previous research was 
conducted on women who received the HPV vaccine only shortly after its approval. Early 
adopters of the HPV vaccine may have been sexually active at younger ages, had more 
sexual partners before vaccination, or had more safety concerns than those who waited a 
few years before receiving the vaccine, and therefore may have been more accepting of 
the vaccine. Current research in needed that also includes later adopters of the vaccine. 
Additionally, past research did not distinguish between sexual acts (vaginal, oral, and 
anal intercourse), which is important since they present different magnitudes of risk for 
infection of STIs. Similarly, those who do not perceive oral or anal acts as “sex” may be 
less likely to protect themselves against STIs related to those acts. Finally, past research 
has not examined the relationship between HPV vaccination and discontinuation of 
sexual health care utilization and perceptions of risk. The current study seeks to 
overcome the limitations of previous research by providing more recent and 
comprehensive results about the relationship between HPV vaccination and sexual 
activity, sexual health care utilization, and perceptions of risk.  
The Current Study 
 The current study examined, within a sample of college women, the relationship 
between HPV vaccination and sexual activity, sexual health care utilization and 
intentions, and perceptions of risk regarding HPV and other STIs. This study advances 
past research regarding the potential relationship between these factors by collecting 
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more precise information about age at each new sexual partner and age at vaccination. 
This additional data allowed for greater analysis of the number of new sexual partners, 
condom usage, and sexual health care utilization since vaccination. Women who have 
never received the HPV vaccine (not vaccinated) or have received some or all of the 
doses (vaccinated) reported information about their sexual partners, sexual practices, use 
of sexual health care services since vaccination as well as intentions to use sexual health 
care services, perceptions of change because of vaccination, and perceptions of risk. 
Emerging research suggests one or two doses of the HPV vaccine are efficacious at 
protecting against HPV types 16 and 18 (Kreimer et al., 2011) and therefore provides 
support for analyzing vaccination status as a dichotomous variable. The primary research 
goals were to examine whether differences exist between women vaccinated and not 
vaccinated against HPV in (1) sexual partners and condom use since vaccination, (2) use 
and intentions to use sexual health care services since vaccination, and (3) perceptions of 
risk and importance of sexual health care use after vaccination. The final goal (4) was to 
measure the perceptions of change because of vaccination among vaccinated women.  
Method 
Survey 
Survey items were adapted from several measures used in previous research. 
Question wording was adjusted for easy comprehension in an online, self-administered 
format. Survey items were reviewed for comprehension and completeness by a team with 
experience in sexual health and health psychology research. 
 Sexual activity. The survey included items to assess number of sexual partners 
(e.g., “In your lifetime, how many men have you had vaginal intercourse with?”), age of 
10 
 
 
 
first intercourse with each new partner (e.g., “What age were you when you had vaginal 
intercourse with the 1st man?”), and condom use frequency with each partner (e.g., “How 
often did you use condoms during vaginal intercourse with the 1st man?” and “How often 
did you use a dental damn when the 1st man performed oral sex on you?”). Responses of 
condom use frequency were reported on a 5-point Likert scale (1 = Never, 5 = Always). 
Women reported total number of partners, age at first sex with each partner, and condom 
use with each partner for each type of intercourse: vaginal intercourse, oral sex 
performed, oral sex received, and anal sex. Items on number of sexual partners and age at 
intercourse were adapted from the National Health and Nutrition Examination Survey 
2009, used by the CDC for data collection in the two previous studies regarding HPV 
vaccination and sexual activity (Taylor et al., 2011; Liddon et al., 2012). Frequency of 
condom use items were adapted from the survey used by Beadnell et al. (2005) for data 
collection regarding sexual risk-taking. 
 Sexual health care utilization. The survey included items to assess utilization of 
and intent to use sexual health care services including pelvic exams, Pap smears, and STI 
testing (e.g., “How many times have you had a Pap smear in the last 3 years?” and “How 
many times do you intend to have a Pap smear in the next 3 years?”). The item measuring 
intention to get tested for an STI was adapted from Boyer, Sieverding, Siller, Gallaread, 
& Chang’s (2007) research on STI screening. All other items were adapted from the 
NHANES survey. 
  Perceptions of risk. The survey included items related to perceptions of risk of 
cervical cancer, genital warts, HPV, and other STIs (e.g., “How likely do you think you 
are to get HPV in your lifetime?”). Responses were reported on a 5-point Likert scale (1 = 
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Very unlikely, 5 = Very likely). The survey also included items related to the perceived 
importance of pelvic exams, Pap smears, STI testing, and condom use (e.g., “How 
important do you think it is to use condoms during vaginal intercourse?”). Responses were 
reported on a 5-point Likert scale (1 = Not important, 5 = Very important). Perception of 
risk items were adapted from research on perceived risk for AIDS (Hansen, Hahn, & 
Wolkenstein, 1990). 
   Perceptions of change. The survey included items assessing women's perception 
of change in condom use because of the vaccine (e.g., "Because you have received the 
HPV vaccine, have you changed how often you use condoms during vaginal 
intercourse?"), change in sexual health care utilization because of the vaccine (e.g., 
"Because you have received the HPV vaccine, have you changed how often you get a Pap 
smear?"), and change in beliefs about STI susceptibility because of the vaccine (e.g., 
"Because you have received the HPV vaccine, has your belief regarding how protected 
you are from sexually transmitted diseases or infections (other than HPV) changed?"). 
Perception items were answered at the end of the survey so they would not influence the 
reporting of actual behaviors. Women could not return to previous sections of the survey 
to adjust their answer of actual behaviors. 
 Demographics. The survey collected demographics and information pertaining to 
HPV vaccination: brand of vaccination, number of doses received, and age at most recent 
dose. 
Procedure 
 The study was approved by the University of Wisconsin – Milwaukee’s IRB. 
Female students, between the ages of 18 and 32, who were enrolled in a course at the 
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University of Wisconsin – Milwaukee (UWM) that allowed extra credit for research 
participation, were invited to complete a survey. UWM is a large, diverse campus in 
which students from all ethnicities, socioeconomic statuses, and religions are enrolled. 
This specific age range was targeted because women who were 26 years old when the 
vaccine first became available, and were therefore the oldest women for whom the 
vaccine was approved, would at the time of this survey be 32 years of age. Participants 
were recruited through SONA, a human subjects pool management system, used by the 
university, and were directed toward an online survey. The first screen of the online 
survey was a consent form in which participants were informed the survey was collecting 
information regarding sexual activity but that no identifying information would be linked 
to their survey. Participants gave their consent for the survey by clicking to the next 
screen. Participants completed the survey in about 15 minutes and received extra credit. 
Statistical Analyses 
 
All data were analyzed with SPSS 17.0. Heterosexual women across groups 
(vaccinated and not vaccinated) were matched on age, race/ethnicity, and poverty. For 
instances in which multiple responses could serve as a match, one response was randomly 
selected. Women were not directly asked how many partners they had before and after 
vaccination. Instead, the age of each partner was reported. The number of sexual partners 
before vaccination was calculated by adding the number of partners before the age of 
vaccination. Partners reported at or after the age of vaccination were totaled to calculate 
the number of partners since vaccination. Number of sexual partners for the not 
vaccinated women was calculated using the matched pair's age of vaccination: this 
allowed for both vaccinated and not vaccinated women to have an equivalent number of 
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years since vaccination. A similar method was used to calculate number of partners 
without a condom before and after vaccination. 
To determine if vaccinated and not vaccinated women differed in sexual practices 
after age of vaccination (Goal 1), paired-samples t-tests were conducted to compare 
number of new partners since vaccination, and number of new partners for which a 
condom was not used since vaccination. Analysis was conducted separately for vaginal, 
oral performed, oral received, and anal intercourse. 
 To analyze sexual health care utilization (Goal 2), paired-samples t-tests were 
conducted on variables measuring number of pelvic exams in the last year, and number of 
Pap smears in the last three years. To ensure reported pelvic exams and Pap smears 
occurred after vaccination, these analyses included only those women who were 
vaccinated one or three full years prior completing the survey. Paired-samples t-tests 
were conducted to analyze intention to use sexual health care among all vaccinated and 
not vaccinated women: how likely participants were to get a pelvic exam in the next year, 
a Pap smear in the next 3 years, and tested for an STI in the next year.  
Three items related to HPV risk perception (HPV, genital warts, and cervical 
cancer) and one item of STI risk perception were averaged to form the scale risk 
perception. Scale reliability (α = .822) was sufficient (Nunnaly, 1978). The six perceived 
importance items (to get a pelvic exam every year, get a Pap smear every 3 years, to get 
tested for STIs, use condoms during vaginal sex, use condoms during oral sex, and use 
condoms during anal sex) were averaged to form a scale representing perceived 
importance of sexual health. The scale reliability (α = .756) was sufficient. Paired-
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samples t-tests were conducted to assess differences between groups using the resulting 
scales of risk perceptions and perceived importance of sexual health (Goal 3). 
Frequencies were conducted on items related to perceived change in condom use 
and sexual health care utilization (Goal 4) to measure whether women who were 
vaccinated believed they changed their behaviors because of the vaccine. T-tests were 
conducted on outcome variables (for each goal) to measure whether, among vaccinated 
women, those vaccinated before and after age 18 differed.  
All dependent variables were non-normal except for age at first sexual 
intercourse. Natural log transformations of all non-normal variables resulted in normal 
distributions, therefore meeting the assumption of normality. Analyses were conducted 
on both raw and transformed data. Results report statistics of raw data for ease of 
comprehension when results from raw and transformed data yield similar results. Any 
discrepant results between raw and transformed data are described. Because violation of 
the assumption of normality may affect power to detect differences, results from 
transformed data are more precise in these instances. Statistics based on unequal 
variances are reported for any instances in which the assumption of equality of variances 
is violated. Since each woman completed the survey only one time, all measurements are 
assumed to be statistically independent of each other, and therefore the assumption of 
independent scores was met. 
Results 
Participants 
 Seven hundred women completed the survey. After removing responses with 
missing data on fields required for matching, the remaining 644 responses were matched 
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on age, race, and poverty status, yielding 156 pairs of heterosexual women (312 
responses). Each pair of responses contained one woman who did not receive the vaccine 
and one woman who did receive the vaccine. After checking for outliers, three responses 
and their pair were removed.  
 Demographics were analyzed for the 153 remaining pairs; 141 contained a 
woman who received all three doses of the vaccine, seven contained a woman who 
received two doses, and five contained a woman who received one dose. Of those who 
did not receive all three doses, five women did not give a reason, three were unsure why 
they never got all three doses, two were still waiting the required time between doses, one 
forgot to get all three doses, and one was unable to pay for the last two doses. Most 
vaccinated women received the Gardasil vaccine (75.9%), one woman received Cervarix 
(0.6%), and many women did not know what brand was received (22.2%). First doses of 
vaccines were received at pediatrician offices (53.6%), gynecologic offices (28.2%), 
primary care physician offices (9.1%), state health department clinics (7.3%), and 
Planned Parenthood clinics (1.8%). Women were vaccinated because their parents got 
them vaccinated (33.8%), a nurse, doctor, or other health care personnel recommended it 
(31.9%), and because the woman wanted to get it (25.5%). Vaccination age ranged from 
12 to 26 (M = 17.48, SD = 1.98). The majority of vaccinated women received the vaccine 
before vaginal intercourse (57.4%), performing oral sex (59.9%), receiving oral sex 
(61.2%), and anal sex (94.6%). 
 For each group (vaccinated and not vaccinated), participants age ranged from 18 
to 28, with mean age of 19.90 (SD = 1.84). The majority of women were Caucasian 
(80.1%). African American (11.4%), Asian (4.7%), Hispanic (2.5%), American Indian 
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(0.6%), and mixed race (0.6%) represented smaller proportions of the sample. About half 
(46.5%) of the women qualified for Federal Pell Grants, an indicator of poverty. All 
women were never married. Religion, health insurance type, and home setting 
classification are reported in Table 1 for vaccinated and not vaccinated women. Most 
women were Christian, held private health insurance, and lived in a suburban setting. 
Vaccinated and not vaccinated women did not differ on any of these demographics.   
 Responses from women who reported they had never had vaginal intercourse (and 
those women's matched pair) were removed before analysis of the outcome variables 
because those questions were not pertinent to women with no sexual experience: 17.2% 
of not vaccinated and 15.8% of vaccinated women reported zero vaginal intercourse 
partners. After removing these 96 participants, 105 pairs (210 responses) were included 
in the analysis of the outcome variables.  
 Women's history of sexual activity ever and before vaccination is reported in 
Table 2. The only difference was that vaccinated women had a significantly higher 
number of vaginal sex partners ever than not vaccinated women, t(104) = 3.14, p = .002. 
Vaccinated and not vaccinated women were not different ages at first vaginal intercourse 
(t(78) = -1.52, p = .133), first time performing oral sex (t(67) = -.57, p = .568), first time 
receiving oral sex (t(68) = -.05, p = .959), or at first anal sex (t(2) = -2.00, p = .184). 
Vaccinated and not vaccinated women did not have different numbers of partners on 
which oral sex was performed (t(94) = .89, p = .375), from which oral sex was received 
(t(102) = 1.15, p = .253), or anal sex (t(92) = -1.35, p = .179). Before vaccination, women 
who were and were not vaccinated did not have different numbers of vaginal sex partners 
(t(78) = 1.38, p = .170), men they performed oral sex on (t(76) = .05, p = .963), men from 
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which they received oral sex (t(77) = .00, p = 1.000), or anal sex partners (t(72) = -.85, p 
= .397). Vaccinated and not vaccinated women did not have different numbers of men 
ever with which they had not used a condom or dental dam at least once during vaginal 
sex (t(15) = .57, p = .579), oral sex performed (t(12) = -1.82, p = .094), or oral sex 
received (t(9) = -.20, p = .843). The low numbers of women who had anal sex provided 
insufficient data to allow analysis of condom use during anal sex. Before vaccination, 
women who were and were not vaccinated did not have different numbers of partners 
with which a condom or dental dam was not used during vaginal sex (t(22) = .49, p = 
.632), oral sex performed (t(19) = .14, p = .894), or oral sex received (t(17) = .00, p = 
1.000). The low numbers of women who had anal sex provided insufficient data to allow 
analysis of condom use during anal sex before vaccination. 
 Vaccinated and not vaccinated women did not differ on use of sexual health care 
services ever. Vaccinated women (M = 2.43, SD = 2.83) were not tested for STIs a 
different number of times than not vaccinated women (M = 2.05, SD = 5.11), t(104) = 
.77, p = .446. Women who were (M = .21, SD = .41) and were not vaccinated (M = .23, 
SD = .68) were not diagnosed with a different number of STIs, t(50) = -.20, p = .844. 
After natural log transformations, women who were vaccinated (M = 1.10, SD = .79) did 
not receive a different number of pelvic exams ever than women who were not 
vaccinated (M = .89, SD = .80), t(54) = 1.63, p = .109. After natural log transformations, 
however, vaccinated women (M = 1.08, SD = .88) received a marginally higher number 
of Pap smears ever than not vaccinated women (M = .83, SD = .75), t(47) = 1.86, p = 
.070. 
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Sexual Activity (Goal 1) 
 Number of partners after vaccination. Means and standard deviations of sexual 
activity after vaccination are reported in Table 3. After vaccination, women who were 
vaccinated reported more vaginal sex partners than women who were not vaccinated, 
t(78) = 2.36, p = .021. After vaccination, women who were and were not vaccinated did 
not have different numbers of men they performed oral sex on (t(76) = .88, p = .383), 
received oral sex from (t(77) = 1.33, p = .189), or anal sex partners (t(75) = -1.59, p = 
.116). 
 Among vaccinated women, those who received the vaccine before age 18 and 
therefore needed parental consent did not report different numbers of partners for vaginal 
intercourse (t(100) = 1.644, p = .103), oral sex received after natural log transformations 
(t(82) = .550, p = .584), and anal sex after natural log transformations (t(14.846) = 1.307, 
p = .211) than women vaccinated after age 18 and not needing parental consent. After 
natural log transformations, women vaccinated before age 18 (M = .96, SD = .81) 
reported a higher number of oral sex performed partners than women vaccinated after age 
18 (M = .58, SD = .66), t(73.492) = 2.342, p = .022. 
 Number of partners without a condom after vaccination. Women who were 
and were not vaccinated did not have different numbers of partners with which a condom 
or dental dam was not used during vaginal sex (t(67) = 1.49, p = .140), oral sex 
performed (t(56) = 1.21, p = .231), oral sex received (t(53) = 1.07, p = .290), or anal sex 
(t(1) = 1.00, p = .500). 
 Among vaccinated women, those who were vaccinated before and after age 18 
did not report different numbers of partners without a condom after vaccination for 
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vaginal intercourse (t(94) = 1.323, p = .189), oral sex received (t(80.958) = 1.575, p = 
.119), or anal sex (t(14) = 1.284, p = .220). Women vaccinated before age 18 (M = 3.63, 
SD = 3.05) reported higher numbers of oral sex performed partners without a condom 
than women vaccinated after age 18 (M = 2.26, SD = 1.84), t(80.000) = 2.536, p = .013). 
Sexual Health Care Utilization (Goal 2)  
 Pelvic exams. After correcting for non-normality of data through natural log 
transformations, vaccinated women (M = .15, SD = .33) did not receive a different 
number of pelvic exams in the past year than not vaccinated women (M = .08, SD = .29), 
t(32) = .88, p = .388. 
 Among vaccinated women, those vaccinated after age 18 (M = 1.09, SD = .77) 
reported receiving more pelvic exams in the last year than women vaccinated before age 
18 (M = .75, SD = .52), t(82) = -2.462, p = .016. 
 Pap smears. Vaccinated women (M = 1.88, SD = 1.52) did not receive a different 
number of Pap smears in the past three years than not vaccinated women (M = 1.42, SD = 
1.20), t(32) = 1.59, p = .121. 
 Among vaccinated women and after natural log transformations to correct for 
non-normality of data, those who received the vaccine after age 18 (M = 1.17, SD = .47) 
reported marginally higher numbers of Pap smears in the last three years than women 
who received the vaccine before age 18 (M = .62, SD = .54) , t(20) = -1.896, p = .072. 
 Intentions to utilize. Women not vaccinated (M = 4.16, SD = 1.11) reported 
higher intentions to get a pelvic exam in the next year than vaccinated women (M = 3.79, 
SD = 1.36) (t(102) = 2.21, p = .029). After log transformations, women not vaccinated (M 
= .33, SD = .49) reported higher intentions to receive a Pap smear in the next three years 
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than vaccinated women (M = .20, SD = .40), t(102) = -2.07, p = .041. After log 
transformations, vaccinated women (M = .64, SD = .60) reported marginally higher 
intentions to get tested for an STI in the next year than women not vaccinated (M = .77, 
SD = .65), t(103) = -1.67, p = .098. 
 Among vaccinated women, those who received the vaccine before (M = 3.98, SD 
= 1.12) and after (M = 4.31, SD = 1.05) age 18 did not reported different intentions to get 
a pelvic exam in the next year, t(108) = -1.548, p = .125. After correcting for non-
normality, women vaccinated after age 18 reported marginally higher intentions to 
receive a Pap smear in the next three years (t(107.865) = -1.755, p = .082) and STIs in the 
next year (t(108) = -1.676), p = .097) than women vaccinated before age 18. 
Perceptions of Risk (Goal 3) 
 Women who were (M = 1.96, SD = .88) and were not (M = 2.11, SD = .92) 
vaccinated did not report different perceptions of risk for HPV-related outcomes and STI 
infection, t(102) = -1.24, p = .218. Vaccinated women (M = 4.87, SD = .71) reported 
higher perceived importance of sexual health care than women not vaccinated (M = 4.40, 
SD = 1.00), t(101) = 4.16, p < .001. 
 Among vaccinated women, those who received the vaccine before and after age 
18 did not report different perceptions of risk for HPV-related outcomes (t(106) = -1.460, 
p = .147) and similar perceived importance of sexual health care (t(106) = -1.163, p = 
.248). 
Perceptions of Change (Goal 4) 
 Sexual activity. The majority of vaccinated women reported they had not 
changed their use of condoms or sexual health care utilization because of receiving the 
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HPV vaccine. Few vaccinated women reported they use condoms less often because of 
the vaccine during vaginal (2.9%), oral (1.0%), and anal sex (0.0%). Some women 
reported they used condoms more often because of the vaccine during vaginal (10.5%), 
oral (1.9%), and anal sex (1.0%). Women vaccinated before and after age 18 did not 
report different change in condom use during vaginal (t(108) = -.189, p = .851), oral 
(t(108) = -.180, p = .858), and anal sex (t(108) = .895, p = .373). 
 Sexual health care utilization. Few vaccinated women reported they get tested 
for an STI less often because of the vaccine (1.0%), get pelvic exams less often because 
of the vaccine (1.0%), and get Pap smears less often because of the vaccine (0.0%). Some 
women reported they get tested for an STI more often because of the vaccine (2.9%), get 
pelvic exams more often because of the vaccine (1.0%), and get Pap smears more often 
because of the vaccine (1.9%). Women vaccinated before and after age 18 did not report 
different change in frequency of pelvic exams (t(108) = .303, p = .763) and Pap smears 
(t(108) = .303, p = .763). 
 Perceived risk. Because of the HPV vaccine, 19.0% of vaccinated women 
reported they believed they were more protected from STIs (other than HPV) than they 
were before getting vaccinated. Women who believed they were more protected from 
STIs other than HPV were similar age and race, and had similar education, religion, and 
poverty status than women who did not believe they were more protected from STIs other 
than HPV. These women were also similar ages at vaccination: women who received the 
vaccine before and after age 18 reported similar change in perceived protection, t(108) = 
-.571, p = .569. No women believed they were less protected.  
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Discussion 
 This study examined the relationship between HPV vaccination and sexual 
activity, sexual health care utilization and intentions to utilize, perceptions of risk for 
HPV related outcomes, and perceived change in sexual behaviors and health care 
utilization. It is the first study to collect data on specific ages of each sexual partner and 
age of vaccination to allow for analysis of sexual behaviors after HPV vaccination. This 
is of particular importance as concerns arise regarding HPV vaccination's relationship to 
sexual activity and sexual health care utilization (Bristol, 2007; Davis et al., 2004; Gibbs, 
2006; Root, 2011; Charo, 2007; Haber et al., 2007). 
 Goal one tested for differences between vaccinated and not vaccinated women in 
number of sexual partners and condom use frequency after vaccination. Results showed 
that vaccinated women had a higher number of vaginal sex partners than not vaccinated 
women. Number of oral sex and anal sex partners were similar, as was condom use 
frequency for vaginal, oral, and anal sex. A larger number of vaginal sex partners among 
vaccinated women may provide some support for the concern that HPV vaccination is 
related to greater sexual activity, and therefore some support for greater communication 
with vaccine recipients about the continued importance of safe sex practices. Greater 
number of sexual partners, however, is not directly indicative of greater risky sexual 
activity. Condom usage during sexual acts and STI testing between partners may provide 
protection for any increase in risk that a higher number of sexual partners would 
introduce. Since number of partners without a condom is similar between vaccinated and 
not vaccinated women, the number of partners during which STI infection is likely is 
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similar for the women. It is likely, then, that vaccinated and unvaccinated women's sexual 
activity does not put them at differing risks for sexual health concerns. 
 Goal two tested for differences between vaccinated and not vaccinated women in 
use of sexual health care services since vaccination and intentions to use sexual health 
care services in the future. Vaccinated and not vaccinated women had similar use of 
sexual health care services since vaccination and similar intentions to get tested for STIs 
in the next year. Not vaccinated women did, however, report higher intentions to receive 
a pelvic exam in the next year and a Pap smear in the next three years. This difference in 
intentions to receive a pelvic exam and Pap smear may be cause for concern and may 
warrant a need for increased communication about the continued importance of sexual 
health care services. 
 It is unclear if these intentions to use sexual health care services will lead to actual 
use of services. The Theory of Planned Behavior (Ajzen, 1991) suggests a relationship 
between intentions and behavior, but future research should study, prospectively, the use 
of sexual health care services in women vaccinated and not vaccinated against HPV. 
 Goal three was to examine the perceptions of risk and perceived importance of 
sexual health between vaccinated and not vaccinated women. Although women reported 
similar perceptions of risk for HPV and HPV-related outcomes, vaccinated women 
reported higher importance of sexual health than women not vaccinated. This may be an 
indication that women who receive the vaccine do so because they perceive sexual health 
to be of higher importance than not vaccinated women. Future research should study, 
prospectively, perceived importance of sexual health in women before and after receipt of 
the HPV vaccine.   
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 Goal four focused on measuring perceptions of change among vaccinated women. 
The majority of vaccinated women reported they had not changed their use of condoms 
because of the vaccine, nor did they change how often they got pelvic exams or Pap 
smears. This finding suggests that vaccinated women continue to perceive condom use 
and sexual health care utilization as important aspects of continued sexual health, despite 
HPV vaccination status. 
 Overall, the results from this study indicate that HPV vaccination is not related to 
greater risky sexual activity or less use of sexual health care services: HPV vaccination 
was not related to earlier sexual debut, decreased condom use, or decreased use of sexual 
health care services such as pelvic exams, Pap smears, and STI testing. Vaccinated 
women may, however, be less likely to utilize sexual health care services in the future. 
These findings may allay concerns about HPV vaccination being linked to increased risky 
sexual activity, but may also highlight the need for education about the need for 
continued use of sexual health care services.  
 This study also examined the differences between women vaccinated before age 
18, when parental consent was required, and after age 18. Since parental consent is not 
required after age 18, women vaccinated after that age are less likely to have received the 
vaccine merely because their parents wanted them to get it. Women vaccinated after age 
18 reported lower numbers of men they performed oral sex on without a condom, and 
higher numbers of pelvic exams and Pap smears in the past. Women vaccinated before 
and after age 18 reported similar perceptions of risk; importance of sexual health care; 
and perceptions of change in sexual activity, sexual health care utilization and 
perceptions of risk since vaccination. The higher rates of protected oral sex and sexual 
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health care utilization in women vaccinated after age 18 may be because the women who 
sought out the vaccine without needing parental consent may be women who take more 
initiative in their sexual health.  
This study's limitations include those related to retrospective data collection and, 
as in research related to the reporting of sexual behaviors, a potential for underreporting 
of sexual behavior. Because women reported sexual activity and sexual health care 
utilization retrospectively, recall error is a potential issue for both vaccinated and not 
vaccinated women. Further research measuring activity prospectively should be 
conducted. Because this was a survey measuring sexual activity, underreporting is a 
potential limitation due to the reporting of socially undesirable behaviors. This survey, 
however, was conducted in an anonymous, online format, with question descriptions 
designed to minimize reporting error (e.g., "Some people use condoms during vaginal 
intercourse to prevent disease or pregnancy. Others do not use condoms. The following 
questions ask how often you used condoms when you had vaginal intercourse with each 
man"). 
Despite limitations and the need for further research, this study provides an 
important foundation for educational efforts related to HPV vaccination. This study 
supports the need for increased communication that HPV vaccination does not lead to 
risky sexual behaviors and the need for increased communication about utilization of 
sexual health care services. Further research should examine women who believe, that 
because of the HPV vaccine, they are more protected from STIs other than HPV. 
Although this study did not find any associations with that belief, it was not the aim of 
the study.  
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Table 1 
 
Religion, Health Insurance, and Home Setting by Vaccination Status 
 
Variable 
Vaccinated 
% 
Not 
Vaccinated 
% 
Religion 
   Christianity 63.6 60.4 
 None 29.1 36.8 
 Other 7.3 2.8 
Health Insurance 
   Private 71.8 62.3 
 Government-Assisted 19.1 26.4 
 None 9.1 11.3 
Home Setting 
   Urban 26.4 30.2 
 Suburban 41.8 45.3 
 Rural 31.8 24.5 
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Table 2  
Means and Standard Deviations of Sexual Behaviors Ever and Before Vaccination by 
HPV Vaccination Status 
 
Vaccinated 
Not 
Vaccinated 
Variable M SD M SD 
Age of first sexual experience 
     Vaginal 16.54 1.56 16.92 1.68 
 Oral Received 16.96 1.77 16.97 1.50 
 Oral Performed 16.60 1.70 16.70 1.52 
 Anal 18.00 1.73 18.67 1.53 
Number of sexual partners ever 
     Vaginal* 5.48 4.55 3.87 3.56 
 Oral Received 3.26 3.00 2.82 2.99 
 Oral Performed 3.89 3.87 3.48 3.30 
 Anal 0.31 0.68 0.46 0.77 
Number of partners before vaccination 
     Vaginal 1.54 2.60 1.20 1.90 
 Oral Received 1.04 1.92 1.04 1.90 
 Oral Performed 1.35 2.43 1.34 2.09 
 Anal 0.07 0.30 0.12 0.44 
Number of sexual partners without a condom ever 
     Vaginal 4.44 5.69 3.56 2.73 
 Oral Received 6.00 4.57 6.30 4.40 
 Oral Performed 5.38 2.93 7.08 3.88 
 Anal 2.00 0.00 2.00 1.41 
Number of partners without a condom before vaccination 
     Vaginal 1.87 3.12 1.57 1.75 
 Oral Received 2.83 3.05 2.83 2.66 
 Oral Performed 3.55 3.12 3.45 2.48 
 Anal 1.86 2.79 1.33 0.82 
Note. All variables measuring the number of partners of number of partners without a 
condom were calculated from reported age and condom use of each partner. 
* p < .05. 
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Table 3 
 
Means and Standard Deviations of Sexual Behaviors after Vaccination by Vaccination 
Status 
 
 
Vaccinated Not Vaccinated 
Variable M SD M SD 
Number of partners after vaccination 
     Vaginal* 3.80 3.62 2.72 2.61 
 Oral Received 2.32 2.26 1.87 1.93 
 Oral Performed 2.49 2.50 2.16 2.31 
 Anal 0.20 0.54 0.36 0.63 
Number of partners without  
condom after vaccination 
     Vaginal 2.03 2.54 1.50 1.70 
 Oral Received 2.67 1.74 2.28 2.00 
 Oral Performed 2.88 2.23 2.39 2.17 
 Anal 1.50 0.71 0.50 0.71 
Note. All variables were calculated from reported age and condom use of each partner. 
* p < .05. 
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